Literature DB >> 925686

The influence of bromocriptine on serotonin neurons.

J Maj, L Gancarczyk, A Rawlów.   

Abstract

Bromocriptine (CB-154) is regarded as a dopamine agonist, hence is used in the treatment of Parkinson's disease. In the paper presented a possibility of the influence of bromocriptine on central serotonin neurons has been studied. It was demonstrated that CB-154, like tryptophan, 5-hydroxytryptophan, LSD or fenfluramine in previous experiments, potentiates the flexor reflex of the spinal rat, and this effect of CB-154 is prevented by serotonin antagonists--cryproheptadine and danitracen. CB-154, like fenfluramine used as a comparative serotonergic agent, rises the body temperature in rabbits. The hyperthermic effect of CB-154 is prevented by cyproheptadine, danitracen and mianserin. Haloperidol prevents the hyperthermia caused by a lower dose of CB-154 or on fenfluramine-induced hyperthermia. The results obtained indicate that CB-154, besides a dopaminomimetic action, possesses central serotonin actions as well.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 925686     DOI: 10.1007/bf01252020

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  29 in total

1.  The effects of serotonergic and antiserotonergic drugs on the flexor reflex of spinal rat: a proposed model to evaluate the action on the central serotonin receptor.

Authors:  J Maj; W Palider; L Baran
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

2.  Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover.

Authors:  S R Snider; C Hutt; B Stein; A L Prasad; S Fahn
Journal:  J Pharm Pharmacol       Date:  1976-07       Impact factor: 3.765

3.  Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

Authors:  A M Johnson; D M Loew; J M Vigouret
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

Review 4.  [On the pharmacology of 9,10-dihydro-10-(1-methyl-4-piperidylidene)-9-anthrol (WA 335), a histamine and serotonin antagonist (author's transl)].

Authors:  G Engelhardt
Journal:  Arzneimittelforschung       Date:  1975-11

5.  Some 5-hydroxytryptamine-like actions of fenfluramine: a comparison with (+)-amphetamine and diethylpropion.

Authors:  P J Southgate; S R Mayer; E Boxall; A B Wilson
Journal:  J Pharm Pharmacol       Date:  1971-08       Impact factor: 3.765

6.  A noel type of substituted piperazine with high antiserotonin potency.

Authors:  W J van der Burg; I L Bonta; J Delobelle; C Ramon; B Vargaftig
Journal:  J Med Chem       Date:  1970-01       Impact factor: 7.446

7.  Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.

Authors:  H Corrodi; K Fuxe; T Hökfelt; P Lidbrink; U Ungerstedt
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

8.  Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.

Authors:  A M Johnson; J M Vigouret; D M Loew
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

9.  Apomorphine: modification of its hyperthermic effect in rabbits by p-chlorophenylalanine.

Authors:  R M Quock; A Horita
Journal:  Science       Date:  1974-02-08       Impact factor: 47.728

10.  Central action of nomifensine.

Authors:  J Maj; Z Kapturkiewicz; J Michaluk
Journal:  Pol J Pharmacol Pharm       Date:  1976 Nov-Dec
View more
  1 in total

1.  A Combination of G Protein-Coupled Receptor Modulators Protects Photoreceptors from Degeneration.

Authors:  Tivadar Orban; Henri Leinonen; Tamar Getter; Zhiqian Dong; Wenyu Sun; Songqi Gao; Alexander Veenstra; Hossein Heidari-Torkabadi; Timothy S Kern; Philip D Kiser; Krzysztof Palczewski
Journal:  J Pharmacol Exp Ther       Date:  2017-11-21       Impact factor: 4.030

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.